On 24 July 2025, Reuters reported that Dr Reddy’s CEO, Erez Israeli, stated the company plans to launch its generic version of Novo Nordisk’s Wegovy® (semaglutide), in 87 countries in 2026, beginning with Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry.
Israeli stated that the “U.S. and Europe will open later… (and) all the other Western markets will be open between 2029 to 2033”, and that he expects Dr Reddy’s generic semaglutide to generate “hundreds of millions of dollars” in sales.
According to Reuters, other Indian drugmakers, including Cipla, Lupin, Biocon and Sun Pharma also plan to launch generic weight-loss drugs following the success of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® (tirzepatide).
In October 2024, Novo Nordisk and each of Mylan Pharmaceuticals (a subsidiary of Viatris), Dr Reddy’s, Apotex and Sun Pharma settled their dispute regarding the validity of Novo Nordisk’s US patent no. 10,335,462 covering specific dosages of semaglutide used to treat type 2 diabetes.